TY - JOUR
T1 - E6 viral protein ratio correlates with outcomes in human papillomavirus related oropharyngeal cancer
AU - Hong, Angela
AU - Zhang, Xiaoying
AU - Jones, Deanna
AU - Zhang, Mei
AU - Lee, C. Soon
AU - Lyons, J. Guy
AU - Veillard, Anne-Sophie
AU - Rose, Barbara
PY - 2016
Y1 - 2016
N2 - Background: The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) Conclusion: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.
AB - Background: The study aimed to identify prognostic markers to improve the management of patients with HPV positive OSCC Methods: We determined the ratio of HPV E6*I and E6*II splice variants by quantitative RT-PCR in 177 HPV positive OSCC and correlated the findings with other clinicopathological data Results: There was no significant difference in locoregional recurrence (HR 1.72 p = 0.24) and death (HR 1.65, p = 0.13) among patients whose tumors had an E6*I/*II ratio ≥1 compared with an E6*I/*II ratio of <1. Univariate analysis showed that patients with E6*I/*II ≥1 OSCC were more likely to have an event. In the multivariable analysis, there was a trend for more events in patients with E6*I/*II ratio ≥1 (HR 1.70, 95% CI 0.95-3.03, p = 0.07) Conclusion: Our data suggest that the use of HPV 16 spliced transcripts may help to predict for poorer outcomes in patients with HPV positive OSCC.
UR - https://hdl.handle.net/1959.7/uws:64616
U2 - 10.1080/15384047.2015.1108489
DO - 10.1080/15384047.2015.1108489
M3 - Article
SN - 1538-4047
VL - 17
SP - 181
EP - 187
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 2
ER -
